Autosomal dominant cerebellar ataxia type III
MONDO:0019793Autosomal dominant cerebellar ataxia (ACDA) type III is a group of neurodegenerative disorders characterized by mostly pure cerebellar syndromes with occasional non-cerebellar signs (e.g. pyramidal signs, peripheral neuropathy, writer's cramp) and includes spinocerebellar ataxia (SCA) type 5 (SCA5), SCA6, SCA11, SCA26, SCA30, and SCA31.
Also known as: ADCA3, ADCAIII, Pure cerebellar syndrome-mild pyramidal signs syndrome, autosomal dominant cerebellar ataxia type 3, autosomal dominant cerebellar ataxia type III
28 clinical trials for this condition and its sub-types, 0 tagged with Autosomal dominant cerebellar ataxia type III itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Autosomal dominant cerebellar ataxia type III
-
Spinocerebellar ataxia type 6 9 trials
-
Spinocerebellar ataxia 45 0 trials
-
Spinocerebellar ataxia type 11 0 trials
-
Spinocerebellar ataxia type 26 0 trials
-
Spinocerebellar ataxia type 30 0 trials
-
Spinocerebellar ataxia type 31 0 trials
-
Spinocerebellar ataxia type 38 0 trials
-
Spinocerebellar ataxia type 41 0 trials
-
Spinocerebellar ataxia type 42 0 trials
1 sub-type
-
Spinocerebellar ataxia type 5 0 trials
-
Robots as rehab coaches: a new approach to retraining coordination in ataxia
Disease control OngoingThis trial tests whether robot-assisted neurorehabilitation can improve coordination, balance, and walking in adults with ataxia, a condition that affects movement control. Participants will receive either robotic or standard rehabilitation, and researchers will measure changes i…
Sponsor: Somogy Megyei Kaposi Mór Teaching Hospital • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New drug could slow rare brain disease that steals balance
Disease control OngoingThis phase 3 trial tests whether the drug troriluzole can slow the progression of spinocerebellar ataxia, a rare genetic disorder that affects coordination and balance. About 300 adults with different types of SCA are randomly assigned to take either troriluzole or a placebo dail…
Phase 3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a drug slow rare brain disease? new study uses Real-World data to find out
Disease control OngoingThis study looks at whether the drug troriluzole can slow the progression of spinocerebellar ataxia (SCA), a rare genetic disease that affects movement and balance. Researchers will compare 909 patients who took troriluzole for up to three years with similar patients who did not …
Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Can a gentle brain zap help people with ataxia walk better?
Symptom relief OngoingThis study tests whether a non-invasive brain stimulation technique called transcranial direct current stimulation (tDCS) can improve movement in people with degenerative ataxia, a rare condition that damages the cerebellum and impairs balance and coordination. Sixteen participan…
Sponsor: University of Cagliari • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC